Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IOS-1002 + unspecified PD-1 antibody |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IOS-1002 | IOS 1002|IOS1002 | LILRB2 Antibody 11 | IOS-1002 is fusion protein comprising a modified version of HLA-B57 fused to IgG4 Fc, which targets the LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1 receptors on immune cells and potentially increases antitumor immune response (PMID: 39199672). | |
unspecified PD-1 antibody | Experimental PD-1 antibody | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05763004 | Phase I | IOS-1002 IOS-1002 + unspecified PD-1 antibody | A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With a PD-1 Monoclonal Antibody in Advanced Solid Tumors | Recruiting | AUS | 0 |